(2-Chloro-4-pyridinyl)methanol
(2-Chloro-4-pyridinyl)methanol, also known as **2-chloro-4-pyridylmethanol**, is an organic compound with the molecular formula C6H6ClNO. It's a white solid with a pungent odor and is used as an intermediate in the synthesis of various pharmaceutical and agrochemical compounds.
Here's why it's important for research:
* **Versatile Intermediate:** (2-Chloro-4-pyridinyl)methanol serves as a building block for synthesizing diverse molecules. Its structure allows for various chemical modifications, making it a valuable tool in medicinal and agricultural chemistry.
* **Potential Applications:** It has been investigated for its potential applications in:
* **Anti-cancer agents:** Studies have explored its potential as an anticancer agent, demonstrating promising activity against certain cancer cell lines.
* **Antimicrobial agents:** Its structural features suggest potential as an antimicrobial agent, which could be valuable for combating infectious diseases.
* **Agrochemicals:** Its properties might be utilized in the development of herbicides or pesticides.
* **Mechanism of Action:** Its biological activity is often attributed to its ability to interact with various biological targets, including enzymes and receptors. Understanding this mechanism of action is crucial for developing new drugs and agrochemicals.
**Key Research Areas:**
* **Synthesis and Modification:** Research focuses on developing efficient and environmentally friendly methods for synthesizing (2-Chloro-4-pyridinyl)methanol and its derivatives.
* **Biological Activity:** Studies investigate its biological activity against various disease targets, including cancer cells, bacteria, and fungi.
* **Structure-Activity Relationships:** Researchers aim to understand the relationship between its molecular structure and its biological activity, which helps in designing more potent and selective compounds.
Overall, (2-Chloro-4-pyridinyl)methanol is a versatile intermediate with potential applications in various fields. Ongoing research aims to unlock its full potential and develop new drugs, agrochemicals, and other valuable products.
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 7062237 |
| CHEMBL ID | 1545251 |
| CHEBI ID | 194637 |
| SCHEMBL ID | 451390 |
Synonyms (39)
| Synonym |
|---|
| (2-chloropyridin-4-yl)methanol |
| smr000206493 |
| MLS000582507 |
| 100704-10-7 |
| 2-chloro-4-hydroxymethylpyridine |
| 2-chloro-4-(hydroxymethyl)pyridine |
| HMS1627E14 |
| AKOS001836524 |
| (2-chloro-4-pyridinyl)methanol |
| CHEBI:194637 |
| HMS2509J07 |
| (2-chloro-pyridine-4-yl)-methanol |
| EN300-62168 |
| (2-chloro-pyridin-4-yl)-methanol |
| AM802825 |
| FT-0649972 |
| 4Y-0721 |
| PB21002 |
| CL0096 |
| 2-chloropyridine-4-methanol |
| SCHEMBL451390 |
| SY007312 |
| mfcd06858767 |
| 4-pyridinemethanol, 2-chloro- |
| (2-chloropyridine-4-yl)methanol |
| UDDVPFLXGOBESH-UHFFFAOYSA-N |
| (2-chloro-4-pyridinyl) methanol |
| 2-chloro-4-pyridinemethanol |
| W-204384 |
| DTXSID00427672 |
| CHEMBL1545251 |
| C2595 |
| (2-chloro-4-pyridinyl)methanol, 97% |
| AC-9503 |
| CS-W003365 |
| STL510982 |
| BBL100022 |
| HY-W003365 |
| Z979439344 |
Drug Classes (2)
| Class | Description |
|---|---|
| pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
| organohalogen compound | A compound containing at least one carbon-halogen bond (where X is a halogen atom). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
| geminin | Homo sapiens (human) | Potency | 0.6513 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 2.5119 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Molecular Functions (2)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (1)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||